Erythromycin lactobionate

Benzamycin, E.e.s, Ery-tab, Eryc, Erygel, Eryped, Erythrerm, Erythrocin, Erythromycin, Eryzole, Ilosone, Ilotycin, Pediazole (erythromycin lactobionate) is a small molecule pharmaceutical. Erythromycin lactobionate was first approved as Ilotycin on 1982-01-01. It is used to treat acne vulgaris, bacterial eye infections, bacterial infections, campylobacter infections, and chancroid amongst others in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
infections	D007239
digestive system diseases	D004066
respiratory tract diseases	D012140
eye diseases	D005128
urogenital diseases	D000091642
skin and connective tissue diseases	D017437

Trade Name

FDA

EMA

Erythrocin, Erythromycin lactobionate (discontinued: Erythrocin, Erythromycin, Erythromycin lactobionate)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Erythromycin lactobionate

Tradename	Company	Number	Date	Products
ERYTHROCIN	Hospira	N-050609 RX	1986-09-24	1 products, RLD, RS

Show 2 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
erythrocin lactobionate	ANDA	2024-02-22
erythrocin stearate	ANDA	2015-07-31
erythromycin lactobionate	ANDA	2024-11-20

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
acne vulgaris	EFO_0003894	D000152	L70
bacterial infections	—	D001424	A49
gonorrhea	DOID_7551	D006069	A54
campylobacter infections	EFO_0007190	D002169	—
whooping cough	EFO_0000650	D014917	A37
chlamydia infections	EFO_0007205	D002690	A74.9
streptococcal infections	EFO_1001476	D013290	—
legionnaires' disease	EFO_0007343	D007877	A48.1
urethritis	EFO_0003878	D014526	N34
bacterial eye infections	—	D015818	—

Show 7 more

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

D: Dermatologicals

— D10: Anti-acne preparations

— D10A: Anti-acne preparations for topical use

— D10AF: Antiinfectives for treatment of acne

— D10AF02: Erythromycin

— D10AF52: Erythromycin, combinations

J: Antiinfectives for systemic use

— J01: Antibacterials for systemic use

— J01F: Macrolides, lincosamides and streptogramins

— J01FA: Macrolides

— J01FA01: Erythromycin

S: Sensory organ drugs

— S01: Ophthalmologicals

— S01A: Antiinfective ophthalmologics

— S01AA: Antibiotics, ophthalmologic

— S01AA17: Erythromycin

HCPCS

Code	Description
J1364	Injection, erythromycin lactobionate, per 500 mg

Clinical

Clinical Trials

1006 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Mycobacterium avium-intracellulare infection	D015270	EFO_0007386	—	1	1	—	2	2	6
Mycobacterium infections	D009164	—	A31.9	1	1	—	1	2	5
Healthy volunteers/patients	—	—	—	—	—	—	1	1	2
Mycobacterium avium complex	D015269	—	—	—	—	—	2	—	2
Otitis media	D010033	EFO_0004992	H66.9	—	—	—	1	—	1
Otitis	D010031	—	—	—	—	—	1	—	1
Nontuberculous mycobacteria	D009170	—	—	—	—	—	1	—	1
Lung diseases	D008171	EFO_0003818	J98.4	—	—	—	1	—	1

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Chronic bronchitis	D029481	—	J42	—	—	1	—	1	2
Bronchitis	D001991	—	J40	—	—	1	—	1	2
Acute disease	D000208	—	—	—	—	1	—	—	1
Sinusitis	D012852	EFO_0007486	J32	—	—	1	—	—	1
Crohn disease	D003424	EFO_0000384	K50	—	—	1	—	—	1
Cardiovascular diseases	D002318	EFO_0000319	I98	—	—	1	—	—	1
Coronary artery disease	D003324	—	I25.1	—	—	1	—	—	1
Myocardial ischemia	D017202	EFO_1001375	I20-I25	—	—	1	—	—	1
Heart diseases	D006331	EFO_0003777	I51.9	—	—	1	—	—	1

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Infections	D007239	EFO_0000544	—	1	1	—	—	4	6
Communicable diseases	D003141	—	—	1	1	—	—	4	6
Hiv infections	D015658	EFO_0000764	B20	1	1	—	—	2	4
Fibrosis	D005355	—	—	—	1	—	—	—	1
Cystic fibrosis	D003550	EFO_0000390	E84	—	1	—	—	—	1

Indications Phases 1

No data

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Respiratory tract infections	D012141	—	J06.9	—	—	—	—	3	3
Pneumonia	D011014	EFO_0003106	J18	—	—	—	—	1	1
Tracheitis	D014136	EFO_0007518	—	—	—	—	—	1	1

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Erythromycin lactobionate
INN	erythromycin
Description	Erythromycin A is an erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. It is an erythromycin and a cyclic ketone. It is functionally related to an erythronolide A. It is a conjugate base of an erythromycin A(1+).
Classification	Small molecule
Drug class	antibiotics (Streptomyces strain)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO